--- title: "Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels" type: "News" locale: "en" url: "https://longbridge.com/en/news/280493677.md" description: "Beam Therapeutics shares rose after promising clinical data from the BEAM-302 trial showed sustained alpha-1 antitrypsin (AAT) levels above the protective threshold, supporting plans for an accelerated FDA approval pathway. The trial demonstrated a well-tolerated safety profile, with no serious adverse events. The company plans to initiate a pivotal cohort in the second half of 2026, aiming to enroll 50 additional patients. Despite a recent rise, technical indicators show mixed momentum, with the stock currently trading below its moving averages. Analysts maintain a Buy rating with a target price averaging $47.57." datetime: "2026-03-25T14:31:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280493677.md) - [en](https://longbridge.com/en/news/280493677.md) - [zh-HK](https://longbridge.com/zh-HK/news/280493677.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280493677.md) | [繁體中文](https://longbridge.com/zh-HK/news/280493677.md) # Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels **Beam Therapeutics Inc.** (NASDAQ:BEAM) shares are up during Wednesday’s premarket session following the release of promising clinical data regarding its treatment BEAM-302. BEAM-302 is Beam’s lead genetic disease program for liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease. AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease. ## Data Show AAT Levels Above Protective Threshold The company announced updated safety and efficacy data from its ongoing Phase 1/2 trial of BEAM-302, highlighting that treatment with 60 mg of the drug led to a mean steady-state total alpha-1 antitrypsin (AAT) level of 16.1 µM. Notably, all patients remained consistently and durably above the 11 µM protective AAT threshold, with a significant reduction in mutant Z-AAT levels. Additionally, the trial demonstrated a well-tolerated safety profile, with no serious adverse events reported. The company plans to initiate a global pivotal cohort in the second half of 2026, further advancing its efforts in treating alpha-1 antitrypsin deficiency (AATD). ## BEAM-302 Pivotal Development Based on feedback from the U.S. Food and Drug Administration (FDA), Beam intends to pursue an accelerated approval pathway for BEAM-302 based on a primary endpoint of AAT biomarkers evaluated over 12 months, with 60 mg as the selected dose. To support a future biologics licensing application (BLA) submission, the company anticipates enrolling approximately 50 additional patients with AATD-associated lung disease, with or without liver disease, in an expansion of the ongoing open-label Phase 1/2 trial. Beam expects to initiate the pivotal cohort in the second half of 2026. ## Technical Indicators Reflect Mixed Momentum Currently, Beam Therapeutics is trading 7.5% below its 20-day simple moving average (SMA) and 8.7% below its 100-day SMA, indicating some short-term weakness. Over the past 12 months, shares have increased by 3.14% and are currently positioned closer to their 52-week highs than lows. The RSI is at 38.84, which is considered neutral territory, while the MACD is at -0.9269, below its signal line at -0.7546, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum. - **Key Resistance**: $29.00 - **Key Support**: $23.50 **Analyst Consensus & Recent Actions:** The stock carries a Buy Rating with an average price target of $47.57. Recent analyst moves include: - **RBC Capital**: Sector Perform (Raises Target to $26.00) (Feb. 25) - **Wedbush**: Outperform (Raises Target to $65.00) (Feb. 25) - **Canaccord Genuity**: Initiated with Buy (Target $74.00) (Feb. 20) Top ETF Exposure - **ARK Innovation ETF** (NYSE:ARKK): 3.60% Weight - **ARK Genomic Revolution ETF** (BATS:ARKG): 4.96% Weight **BEAM Stock Price Activity:** Beam Therapeutics shares were up 2.71% at $24.60 during premarket trading on Wednesday, according to Benzinga Pro data. _Image via Shutterstock_ ### Related Stocks - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Beam Therapeutics Inc. (BEAM.US)](https://longbridge.com/en/quote/BEAM.US.md) ## Related News & Research - [BUZZ-Beam Therapeutics rises after gene-editing drug shows promise in rare lung and liver disease](https://longbridge.com/en/news/280463519.md) - [Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing](https://longbridge.com/en/news/281490970.md) - [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/en/news/281025352.md) - [ARK Investment Management LLC Increases Position in Beam Therapeutics Inc. $BEAM](https://longbridge.com/en/news/277903450.md) - [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/en/news/281024362.md)